Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

ClinicalTrials.gov ID: NCT03792841

Public ClinicalTrials.gov record NCT03792841. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager Acapatamab in Subjects With Metastatic Castration-resistant Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in subjects with metastatic castration-resistant prostate cancer, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

Study identification

NCT ID: NCT03792841
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Amgen; Industry
Enrollment: 212 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 5, 2019 (Actual)
Primary completion: Jun 29, 2023 (Actual)
Completion: Jun 29, 2023 (Actual)
Last update posted: Oct 16, 2025

2019 – 2023

United States locations

U.S. sites: 13
U.S. states: 9
U.S. cities: 12

Facility	City	State	ZIP	Site status
El Camino Hospital	Campbell	California	95008	—
City of Hope National Medical Center	Duarte	California	91010	—
City of Hope at Long Beach Elm	Long Beach	California	90813	—
University of California Los Angeles	Los Angeles	California	90095	—
Emory University	Atlanta	Georgia	30322	—
Indiana University	Indianapolis	Indiana	46202	—
University of Iowa Hospitals and Clinics	Iowa City	Iowa	52242	—
Tulane Medical Center	New Orleans	Louisiana	70112	—
Washington University	St Louis	Missouri	63110	—
Comprehensive Cancer Centers of Nevada	Las Vegas	Nevada	89169	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Weill Cornell Medical College	New York	New York	10065	—
University of Texas Southwestern Medical Center	Dallas	Texas	75390	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03792841, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 16, 2025 · Synced Oct 27, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03792841 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →